A Response to: Letter to the Editor Regarding “Cost-Effectiveness of Elranatamab Versus Current Therapies for the Management of Patients with Triple-Class Exposed, Relapsed and Refractory Multiple Myeloma, Including Other Bispecific and Physician’s Choice of Treatment in Spain”

and appreciate their interest and thoughtful analysis of our study.We welcome the opportunity to clarify certain points and provide additional context regarding the methodology and interpretation of our findings.While we acknowledge the valuable perspectives raised, we would like to address specific aspects where further explanation may help avoid potential misinterpretation. RELATIVE EFFICACY OF ELRANATAMAB VERSUS TECLISTAMAB Uncertainty in Treatment ComparisonIn relation of the mentioned differences in the timing of the clinical studies for elranatamab and teclistamab, while the emergence of the COVID-19 pandemic, including the circulation of variants such as the Delta variant of SARS-CoV-2-which was designated by the WHO in May 2021-may have influenced some of the outcomes observed in these trials, both studies recruited patients during periods of high COVID-19 waves, coincident with the initial appearance in 2020 and also several pandemic peaks during 2021 (MajesTEC-1 enrolled from